Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
Abstract Discontinuing long‐term pharmacotherapy for insomnia can result in rebound insomnia or withdrawal symptoms and suboptimal treatment. Post hoc analyses evaluated rebound insomnia and withdrawal symptoms among the subset of subjects from a phase III, 12‐month, global, multicenter, randomized,...
Saved in:
Main Authors: | Yoshikazu Takaesu (Author), Masahiro Suzuki (Author), Margaret Moline (Author), Kate Pinner (Author), Kanako Inabe (Author), Yurie Nishi (Author), Kenichi Kuriyama (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics
by: Yumi Aoki, et al.
Published: (2022) -
Safety and Efficacy of Lemborexant in Insomnia Patients: Results of a Postmarketing Observational Study of Dayvigo® Tablets
by: Kazuo Mishima, et al.
Published: (2024) -
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Satish Dayal, et al.
Published: (2021) -
Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
by: Ishani Landry, et al.
Published: (2020) -
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Ishani Landry, et al.
Published: (2021)